EP Patent

EP0858341B1 — Combination therapy for advanced cancer comprising temozolomide and cisplatin

Assigned to Merck Sharp and Dohme LLC · Expires 2001-10-24 · 25y expired

What this patent protects

There is disclosed a method for treating advanced cancer in patients in need of such treating. Temozolomide and cisplatin are administered in combination in amounts sufficient to achieve a clinical response.

USPTO Abstract

There is disclosed a method for treating advanced cancer in patients in need of such treating. Temozolomide and cisplatin are administered in combination in amounts sufficient to achieve a clinical response.

Drugs covered by this patent

Patent Metadata

Patent number
EP0858341B1
Jurisdiction
EP
Classification
—
Expires
2001-10-24
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.